doi:10.1093/ajcn/81.5.1026
A clinical trial involving 42 PD patients (2:1 randomized to NAC or control) demonstrated that a 3-month NAC regimen (50 mg/kg intravenous weekly plus 600 mg oral twice daily, skipping oral doses on infusion days) significantly increased dopamine transporter binding compared with the control group
5, 2025), and Medical Chemical Corporation (July 9, 2025)
ETHICAL & SUSTAINABLE | These brands are transparent about sourcing, manufacturing practices, and ingredient integrity
10.1002/neu.20006 16 CzabotarP
Antioxidant Substrate Availability GLP-1RAs demonstrate anti-inflammatory [80] and antioxidant-associated effects [81] across both preclinical and clinical studies, although findings are not entirely consistent [82]